OnusBio is a biotechnology company developing new medicines for nervous system disorders, focusing on non‑addictive treatments for neuropathic pain and disease‑modifying therapies for traumatic brain injury.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with neuropathic pain often rely on opioid or other addictive medications, which carry significant risk of dependence and may provide insufficient relief. Individuals who suffer traumatic brain injury (TBI) lack therapies that directly protect or restore damaged neuronal and glial networks, leading to progressive neurological decline.
Solution
OnusBio is developing small‑molecule drug candidates that target specific neural pathways implicated in chronic neuropathic pain and TBI‑induced neurodegeneration. By leveraging established scientific insights together with advanced data‑analytics platforms, the company aims to identify and optimize non‑addictive compounds that can both alleviate pain and modify disease progression. The preclinical programs are structured to reach IND‑enabling milestones within two years, positioning the candidates for rapid transition into clinical testing. This approach seeks to provide clinicians with safer, mechanism‑based therapies that address the underlying pathology rather than merely managing symptoms.
Target Audience
Primary customers are pharmaceutical partners and research institutions seeking novel, non‑addictive pain therapeutics and disease‑modifying treatments for traumatic brain injury.
Features
- Utilization of proprietary data‑analytics pipelines to prioritize targets and predict compound efficacy in nervous system disorders
- Focus on non‑addictive pharmacology for neuropathic pain, reducing reliance on opioids
- Development of disease‑modifying agents that engage scientifically validated targets to protect neuronal and glial networks after TBI
- Early‑stage discovery and preclinical programs designed to achieve IND‑enabling data within a two‑year timeline
- Integration of translational biomarkers to assess target engagement and therapeutic impact in animal models